(lp0
S'Griffin Lifts Price Target on ZIOPHARM Oncology Inc.  Ahead of ... Smarter Analyst - Feb 9, 2017 Griffin analyst Keith Markey sees golden prospects ahead for ZIOPHARM Oncology Inc. , particularly taking into account the seven clinical trials the firm has forthcoming on the table for this year; trials which the analyst commends as&nbsp;...ZIOPHARM Oncology, Inc.  added about 7.4 percent in value since last ... - The Independent Republic'
p1
aS"Better Buy: Ziopharm Oncology, Inc. vs. Juno Therapeutics Motley Fool - Nov 3, 2016 And although it hasn't been as closely associated with CAR-T as Juno Therapeutics, Ziopharm Oncology  is part of a collection of entities  developing a therapeutic pipeline in the same class,&nbsp;...ZIOPHARM Announces Four Presentations at the 2016 ASH Annual Meeting - GlobeNewswire "
p2
aS"The Reason Behind ZIOPHARM Oncology Inc.'s 11% Gain Motley Fool - Nov 10, 2016 Shares of ZIOPHARM Oncology , a clinical-stage biopharmaceutical company focused on the development of various immunotherapeutic cancer treatments, surged as much as 11% during Thursday's trading session after the company&nbsp;...Stock Update : ZIOPHARM Oncology Inc. Reports Third Quarter 2016 ... - Smarter Analyst"
p3
aS"Company Update : ZIOPHARM Oncology Inc. Announces 4Q:16 Financial ... Smarter Analyst - Feb 16, 2017 ZIOPHARM Oncology Inc.  announced financial results for the fourth quarter ended December 31, 2016, and provided an update on the Company's recent activities.Ziopharm 4Q Loss 11 Cents a Share  - InvestopediaZIOPHARM Reports Fourth-Quarter 2016 Financial Results and Provides Update on ... - GlobeNewswire "
p4
aS'Griffin Commends ZIOPHARM Oncology Inc.  Following Suspension Of Breast ... Smarter Analyst - Feb 27, 2017 ZIOPHARM Oncology Inc.  has indicating the firm will be shifting its R&amp;D pipeline, centering its IL-12 gene therapy program on glioblastoma following the suspension of future development of its breast cancer therapy program.ZIOPHARM Oncology Inc  Rating Lowered to Sell at Zacks Investment Research - Sports Perspectives'
p5
aS'Company Update : ZIOPHARM Oncology Inc. And Intrexon Corp To ... Smarter Analyst - Jan 10, 2017 ZIOPHARM Oncology Inc.  and Intrexon Corp  announced the signing of a Cooperative Research and Development Agreement  with the National Cancer Institute  for the development of adoptive cell transfer&nbsp;...'
p6
aS"Analyst Observation On 2 Stocks: ZIOPHARM Oncology, Inc. , DHI Group ... Post Analyst - 17 hours ago Wall Street is only getting more bullish on the stock, with 1 of analysts who cover ZIOP having a buy-equivalent rating. Analysts have placed a $23 price target on ZIOPHARM Oncology, Inc., suggesting a 262.2% gain from recent close. It's currently ...Company Stock Price of ZIOPHARM Oncology Inc  Decreases -7.84% - Times Money"
p7
aS'Better Buy: Ziopharm Oncology, Inc. vs. Celgene Motley Fool - Jun 18, 2016 One of the coolest kids on the T-cell block to receive a market beatdown was clinical-stage Ziopharm Oncology, Inc. .'
p8
aS'ZIOPHARM Oncology Inc  Moves Higher on Volume Spike for March 10 Equities.com - Mar 10, 2017 ZIOPHARM Oncology Inc  traded on unusually high volume on Mar. 10, as the stock gained 7.82% to close at $6.89. On the day, ZIOPHARM Oncology Inc saw 1.97 million shares trade hands on 8,502 trades. Considering that the stock averages only a&nbsp;...ZIOPHARM Oncology, Inc. : Analyst Rating Changes and PT Levels - Post Analyst'
p9
aS'ATR Check for ZIOPHARM Oncology Inc  Davidson Register - 13 hours ago Active traders have a wide variety of technical indicators at their disposal for completing technical stock analysis. Presently, the 14-day ATR for ZIOPHARM Oncology Inc  is spotted at 0.28. First developed by J. Welles Wilder, the ATR may assist ...'
p10
a.